An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - a type of ...
This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Some medications FDA-approved for type 2 diabetes can promote weight loss. Diabetes medications for weight loss include Ozmepic®, ...
The landscape of diabetes management is undergoing a remarkable transformation. Groundbreaking research has uncovered surprising cardiovascular benefits tied to modern medications, offering new hope ...
An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—a type of ...
A new and increasingly widely used diabetes medication may have additional health benefits for older adults, according to new research which looked at data from more than 300,000 patients who have ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A specific type of diabetes medication has been associated with a lower ...
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and fenofibrates are associated with a reduced risk for diabetic macular edema (DME) in patients with type 2 diabetes, while calcium channel ...
The search for effective dementia prevention continues to challenge medical researchers worldwide. Now, a major study published in JAMA Neurology reveals that certain medications used to treat type 2 ...
A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, also known as gliflozins, ...
Whether you have type 2 diabetes, obesity or just a few extra pounds that you'd like some help shedding, chances are you're one of the millions of adults worldwide who heard about Novo Nordisk's ...
These meds are sometimes prescribed off-label for people with overweight or obesity. Most of these diabetes drugs promote weight loss by suppressing appetite and making you feel fuller. You might have ...